Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

110.59 -0.41 (-0.37%)
Streaming Delayed Price Updated: 3:57 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
68 69 Next >
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by 
Via Benzinga
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging... 
Via Benzinga
The Latest Analyst Ratings for BioNTech
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
What To Know About Redburn Partners's Upgrade of BioNTech
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
3 Ugly Stocks That Actually Hide Beautiful Potential
While these underrated stocks with potential has about as much appeal as brown guacamole, they’re actually quite intriguing. 
Via InvestorPlace
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy. 
Via The Motley Fool
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
From BioNTech SE
Via GlobeNewswire
Expert Ratings for BioNTech
Via Benzinga
BioNTech Se (BNTX) Q1 2023 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2023. 
Via The Motley Fool
A Look Into BioNTech Inc's Price Over Earnings
Via Benzinga
7 Deeply Undervalued Growth Stocks to Buy in June
Investors may see significant rewards betting on these best undervalued growth stocks for June. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Benzinga 
Via Benzinga
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
Via Benzinga
Why Pfizer Stock Slipped by 2% Today
The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares. 
Via The Motley Fool
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with... 
Via Benzinga
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ: NVDA)... 
Via Benzinga
Why Novavax, Pfizer And BioNTech Shares Are Rising Today
Shares of vaccine makers Novavax Inc (NASDAQ: NVAX), Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) a 
Via Benzinga
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales. 
Via The Motley Fool
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
Palo Alto Networks To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Thursday
Needham raised the price target for Dynatrace, Inc. (NYSE: DT) from $52 to $56. Needham analyst James Ricchiuti maintained a Buy rating. Dynatrace shares gained 1.9% to $47.95 in pre-market trading. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2023
Via Benzinga
Why Matinas BioPharma Stock Is Sinking Today
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have ended an mRNA-based collaboration. 
Via Benzinga
Woodstock For Capitalists
Good Morning Everyone! Regional bank PacWest is up 34% in pre-market after being up 81% Friday. They slashed their dividend to conserve capital. With a 19% short interest on the stock, there is... 
Via Benzinga
WHO Ends Global Emergency Status for COVID-19, Virgin Galactic Plans To Launch Space Tourism In Q2, Berkshire Hathaway Has No Intentions To Take Control Of Occidental Petroleum: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations
The launch of an updated booster could increase demand. 
Via Investor's Business Daily
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback